Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 7/20 | 0.58 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.58 |
| ▸ | LGALS4 | P56470 | 2/20 | 0.58 |
| ▸ | IGF2R | P11717 | 3/20 | 0.51 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CD69 | Q07108 | 1/20 | 0.42 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.40 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.40 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.40 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16999977 | 1.00 | LGALS3 (0.58) | LGALS3LGALS8LGALS4IGF2RCHIA | |
| SCHEMBL16641977 | 1.00 | LGALS3 (0.58) | LGALS3LGALS8LGALS4IGF2RCHIA | |
| SCHEMBL16996680 | 0.96 | LGALS3 (0.58) | LGALS3LGALS8LGALS4IGF2RCHIA | |
| SCHEMBL17849185 | 0.95 | LGALS3 (0.54) | LGALS3LGALS8LGALS4IGF2RCHIA | |
| SCHEMBL16641974 | 0.95 | LGALS3 (0.54) | LGALS3LGALS8LGALS4IGF2RCHIA | |
| SCHEMBL16641972 | 0.89 | LGALS3 (0.52) | LGALS3LGALS8LGALS4IGF2RCHIA | |
| SCHEMBL17465828 | 0.89 | LGALS3 (0.52) | LGALS3LGALS8LGALS4IGF2RCHIA | |
| SCHEMBL16999972 | 0.89 | LGALS3 (0.52) | LGALS3LGALS8LGALS4IGF2RCHIA | |
| SCHEMBL19726142 | 0.88 | LGALS3 (0.73) | LGALS3LGALS8LGALS4IGF2RCHIA | |
| SCHEMBL19726152 | 0.86 | LGALS3 (0.66) | LGALS3LGALS8LGALS4IGF2RCHIA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170035890-A1 | Coagulation Factor IX Conjugates | NOVO NORDISK HEALTHCARE AG (CH) | 2017-02-09 | — | — | US | disclosed |
| US-20160120953-A1 | Factor VIII Conjugates | NOVO NORDISK AS (DK) | 2016-05-05 | — | — | US | disclosed |
| US-20150225710-A1 | Coagulation Factor IX Conjugates | NOVO NORDISK A/S | 2015-08-13 | — | — | US | disclosed |
| US-20150225711-A1 | Factor VII Conjugates | NOVO NORDISK HEALTHCARE AG (CH) | 2015-08-13 | — | — | US | disclosed |
| US-20150224203-A1 | Factor VIII Conjugates | NOVO NORDISK A/S (DK) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160120953-A1 | Factor VIII Conjugates | F8, F13B, F13A1 | LGALS3 2320/4885LGALS8 919/4885LGALS4 2059/4885 |
| US-20170035890-A1 | Coagulation Factor IX Conjugates | F9, F13B, F13A1 | LGALS3 1443/4885LGALS8 2103/4885LGALS4 2684/4885 |
| US-20150225710-A1 | Coagulation Factor IX Conjugates | F9, F13B, F13A1 | LGALS3 1443/4885LGALS8 2103/4885LGALS4 2684/4885 |
| US-20150224203-A1 | Factor VIII Conjugates | F8, F13B, F13A1 | LGALS3 2320/4885LGALS8 919/4885LGALS4 2059/4885 |
| US-20150225711-A1 | Factor VII Conjugates | F7, F13B, F13A1 | LGALS3 1103/4885LGALS8 904/4885LGALS4 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.